(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Michael-Jubeli R et al. High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. 2011 J. Lipid Res. pmid:20952798
Lama-Muñoz A et al. New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. 2011 J. Agric. Food Chem. pmid:21265536
Brasser AJ et al. Presence of wax esters and squalene in human saliva. 2011 Arch. Oral Biol. pmid:21247555
Arguedas A et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. 2011 Hum Vaccin pmid:21285531
Manuel O et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. 2011 Clin. Infect. Dis. pmid:21288852
Alghisi F et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. 2011 Thorax pmid:21228426
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Arias JL et al. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. 2011 ACS Nano pmid:21275408
van den Brand JM et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. 2011 J. Virol. pmid:21209108
Calabro S et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. 2011 Vaccine pmid:21215831
Javelle E et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. 2011 Vaccine pmid:21172376
Montagnani S et al. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. 2011 Ann Pharmacother pmid:21189364
Esposito S et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. 2011 Vaccine pmid:21199699
Lopez P et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. 2011 J. Infect. Dis. pmid:21606530
Cen-Pacheco F et al. Cytotoxic oxasqualenoids from the red alga Laurencia viridis. 2011 Eur J Med Chem pmid:21616566
Raouane M et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. 2011 J. Med. Chem. pmid:21561161
Nowosielski M and Hoffmann M Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? 2011 J Mol Model pmid:21562825
Hernández-García I et al. [Adverse events after administration of A/H1N1 vaccine to patients]. 2011 Med Clin (Barc) pmid:20199781
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Vesikari T et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. 2011 N. Engl. J. Med. pmid:21995388
Bernstein DI Vaccines for cytomegalovirus. 2011 Infect Disord Drug Targets pmid:22309618
Fox CB et al. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. 2011 Pharm Dev Technol pmid:20550484
Fabbiani M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. 2011 Vaccine pmid:21349364
Gill S et al. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. 2011 Cell Metab. pmid:21356516
Niehaus TD et al. Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21746901
Kaya K et al. Thraustochytrid Aurantiochytrium sp. 18W-13a accummulates high amounts of squalene. 2011 Biosci. Biotechnol. Biochem. pmid:22056449
Cheong HJ et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. 2011 Clin. Vaccine Immunol. pmid:21715575
Soto G et al. Acetoacetyl-CoA thiolase regulates the mevalonate pathway during abiotic stress adaptation. 2011 J. Exp. Bot. pmid:21908473
Celia C et al. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. 2011 Expert Opin Drug Deliv pmid:22077480
Tsai TF MF59 adjuvanted seasonal and pandemic influenza vaccines. 2011 Yakugaku Zasshi pmid:22129867
Puig-Barberà J et al. MF59™-adjuvanted seasonal influenza vaccine in young children. 2011 Expert Rev Vaccines pmid:22043952
Viganò A et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. 2011 Clin. Vaccine Immunol. pmid:21795458
Huijskens E et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. 2011 Clin. Vaccine Immunol. pmid:21795459
Pollard AJ and Hill AV Antibody repertoire: embracing diversity. 2011 Sci Transl Med pmid:21795586
Okike IO et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. 2011 Vaccine pmid:21742005
Kowert BA and Watson MB Diffusion of organic solutes in squalane. 2011 J Phys Chem B pmid:21780767
Bildstein L et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. 2011 Eur J Pharm Biopharm pmid:21784150
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Zuccotti GV et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. 2011 Diabet. Med. pmid:21916971
Meyer K et al. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. 2011 PLoS ONE pmid:21887300
Broeders NE et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. 2011 Clin J Am Soc Nephrol pmid:21921153
Achiraman S et al. Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? 2011 Theriogenology pmid:21924481
Brito LA et al. An alternative renewable source of squalene for use in emulsion adjuvants. 2011 Vaccine pmid:21723355
Weyermann C et al. Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. 2011 J. Forensic Sci. pmid:20707835
Wu J et al. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. 2011 Arch. Virol. pmid:21110049
Packwood DM and Phillips LF A stochastic, local mode study of neon-liquid surface collision dynamics. 2011 Phys Chem Chem Phys pmid:21042647
Andrews N et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. 2011 J. Infect. Dis. pmid:21148494
Kajaste-Rudnitski A et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. 2011 AIDS pmid:21150561
Launay O et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. 2011 J. Infect. Dis. pmid:21628666
Piccialli V et al. Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. 2011 Molecules pmid:21709619
Iannazzo S Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. 2011 J Prev Med Hyg pmid:21710816
Seubert A et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21690334
Khurana S et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. 2011 Sci Transl Med pmid:21632986
Zhang LW et al. Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. 2011 Int J Nanomedicine pmid:21556344
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Réjiba S et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. 2011 Nanomedicine pmid:21419876
Banzhoff A et al. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. 2011 Hum Vaccin pmid:21422814
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Ambike A et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. 2011 Langmuir pmid:21413743
Gao J et al. Laser-induced acoustic desorption/atmospheric pressure chemical ionization mass spectrometry. 2011 J. Am. Soc. Mass Spectrom. pmid:21472571
Weschler CJ et al. Squalene and cholesterol in dust from danish homes and daycare centers. 2011 Environ. Sci. Technol. pmid:21476540
Cauda V et al. "Liquid-phase calcination" of colloidal mesoporous silica nanoparticles in high-boiling solvents. 2011 J. Am. Chem. Soc. pmid:21480591
Griffiths PD et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. 2011 Lancet pmid:21481708
Liu CL et al. The direct observation of secondary radical chain chemistry in the heterogeneous reaction of chlorine atoms with submicron squalane droplets. 2011 Phys Chem Chem Phys pmid:21455529
Inagaki YS et al. Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. 2011 New Phytol. pmid:21501172
Garcia-Sicilia J et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. 2011 Vaccine pmid:21504774
O'Hagan DT et al. MF59 adjuvant: the best insurance against influenza strain diversity. 2011 Expert Rev Vaccines pmid:21506643
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. 2011 Hum Vaccin pmid:21508673
Ačimovič J et al. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. 2011 Biochem. Biophys. Res. Commun. pmid:21531203
Siedenburg G and Jendrossek D Squalene-hopene cyclases. 2011 Appl. Environ. Microbiol. pmid:21531832
Tsai TF et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. 2011 Scand. J. Infect. Dis. pmid:21534891
Esposito S et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. 2011 Pediatrics pmid:21464195
Esposito S et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. 2011 Nephrol. Dial. Transplant. pmid:20974645
Montana M et al. Safety review: squalene and thimerosal in vaccines. 2010 Nov-Dec Therapie pmid:21176760
Voyron S et al. Antifungal activity of bis-azasqualenes, inhibitors of oxidosqualene cyclase. 2010 Mycoses pmid:19549106
van Himbergen TM et al. Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. 2010 Arterioscler. Thromb. Vasc. Biol. pmid:19834104
Keitel W et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. 2010 Vaccine pmid:19835829
Brunner R et al. The ABC of clinical and experimental adjuvants--a brief overview. 2010 Immunol. Lett. pmid:19895847
Eroglu E and Melis A Extracellular terpenoid hydrocarbon extraction and quantitation from the green microalgae Botryococcus braunii var. Showa. 2010 Bioresour. Technol. pmid:20005092
Kalvodova L Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. 2010 Biochem. Biophys. Res. Commun. pmid:20018176
Kimura M et al. Protostadienol synthase from Aspergillus fumigatus: functional conversion into lanosterol synthase. 2010 Biochem. Biophys. Res. Commun. pmid:19951700
Waddington CS et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. 2010 BMJ pmid:20508026
Beck F et al. Queries about vaccines containing squalene. 2010 Immunol. Cell Biol. pmid:20157330
Gerpe A et al. Naftifine-analogues as anti-Trypanosoma cruzi agents. 2010 Eur J Med Chem pmid:20163894
Warleta F et al. Squalene protects against oxidative DNA damage in MCF10A human mammary epithelial cells but not in MCF7 and MDA-MB-231 human breast cancer cells. 2010 Food Chem. Toxicol. pmid:20138105
Sugihara N et al. Novel fractionation method for squalene and phytosterols contained in the deodorization distillate of rice bran oil. 2010 J Oleo Sci pmid:20103978
Chen CC et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. 2010 Eur J Pharm Biopharm pmid:20060469
Spanova M et al. Effect of lipid particle biogenesis on the subcellular distribution of squalene in the yeast Saccharomyces cerevisiae. 2010 J. Biol. Chem. pmid:20032462
Tsai T et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. 2010 Vaccine pmid:19969117
Pietrella D et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. 2010 Vaccine pmid:20038431
Gasparini R et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. 2010 Int. J. Clin. Pract. pmid:20039974
De Luca C and Valacchi G Surface lipids as multifunctional mediators of skin responses to environmental stimuli. 2010 Mediators Inflamm. pmid:20981292
Bildstein L et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. 2010 J Control Release pmid:20691740
Weiss TL et al. Raman spectroscopy analysis of botryococcene hydrocarbons from the green microalga Botryococcus braunii. 2010 J. Biol. Chem. pmid:20705610
Nakagawa K et al. gamma-Tocotrienol reduces squalene hydroperoxide-induced inflammatory responses in HaCaT keratinocytes. 2010 Lipids pmid:20714817
Black S et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. 2010 Vaccine pmid:20813217
Vesikari T et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. 2010 Pediatrics pmid:20819892
Pili B et al. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. 2010 Nanoscale pmid:20820745
Beran J et al. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. 2010 Clin Ther pmid:21316535